ALLERGOLOGIE is a prominent academic journal dedicated to the field of immunology and allergy, published by DUSTRI-VERLAG DR KARL FEISTLE in Germany. Since its inception in 1978, the journal has provided a vital platform for researchers, clinicians, and students to disseminate their findings, share insights, and foster advancements in the understanding of allergic diseases and immunological responses. With an ISSN of 0344-5062 and an E-ISSN of the same number, it is a respected source within its category, currently ranked in the 2023 Q4 of the Scopus metrics in immunology and allergy, reflecting its commitment to quality and scholarly rigor. Although not fully open access, ALLERGOLOGIE makes significant contributions to the dialogue on allergy-related topics, encouraging engagement from its readership through a diverse array of articles that span from clinical trials to innovative research methods. This journal continues to be an essential resource for anyone involved in the pursuit of knowledge in allergy and immunology.

The Revue Francaise d'Allergologie, an esteemed publication in the field of Immunology and Allergy, is published by ELSEVIER MASSON, CORP OFF in France. This journal plays a pivotal role in disseminating significant findings and advancements in allergy research and immunotherapy, reflecting the latest trends and challenges in these rapidly evolving areas. As part of its commitment to scholarly rigor, the journal encompasses a wide range of topics pertinent to allergology, aiming to bridge the gap between clinical practice and academic research. Although currently not listed as open access, it provides critical insights essential for researchers, professionals, and students alike, ensuring the advancement of knowledge and therapeutic strategies in allergy and immunology. With its impact factor and positioning in the Q4 category, it serves as a valuable resource, aiding in the education and development of future leaders in the field. The Revue Francaise d'Allergologie continues to be a vital platform for the exchange of innovative ideas and findings from 2009 to the present.

Welcome to the Allergo Journal, a pivotal publication in the field of Immunology and Allergy, housed under the esteemed SPRINGER HEIDELBERG publishing house. With an ISSN of 0941-8849 and E-ISSN 2195-6405, the journal has been serving the scientific community since its inception in 1994. Although its Scopus coverage was discontinued in 2017, the journal remains significant, ranked #135 out of 186 in its category and positioned in the 27th percentile, reflecting its contributions to vital research in allergy and immunological disorders. While the journal is not an open access publication, it continues to provide a platform for rigorous academic discourse and advances in the study of allergens and immune response. The Allergo Journal stands as a crucial resource for researchers, professionals, and students dedicated to deepening their understanding of allergies and immunology, fostering advancements in therapy and comprehensive patient care.

ALLERGY is a leading international journal published by WILEY, dedicated to advancing the understanding of allergic diseases and immunology. With an ISSN of 0105-4538 and an E-ISSN of 1398-9995, this esteemed journal has been at the forefront of the field since its inception in 1948 and continues to publish high-quality research up until 2024. Positioned in the Q1 category for both Immunology and Allergy, ALLERGY ranks impressively within the top percentiles of its categories, underscoring its significant impact, as reflected in its Scopus rankings (#11 out of 233 in Immunology and Allergy, and #14 out of 236 in Immunology and Microbiology). Researchers and practitioners accessing this journal can expect a rigorous selection of peer-reviewed articles that address current challenges, innovative therapies, and advancements in the immunological sciences. Although it is not an open-access journal, ALLERGY remains vital for academics, healthcare professionals, and students alike, fostering a deeper understanding of the mechanisms and treatments associated with allergies.

Lupus Science & Medicine is a leading open-access journal published by the BMJ Publishing Group, dedicated to advancing the understanding and treatment of lupus and related autoimmune diseases. Since its establishment in 2014, the journal has fostered an academic environment for researchers, healthcare professionals, and students, providing a platform for high-quality, evidence-based studies. With a notable impact in the fields of immunology and rheumatology, it currently holds a Q1 ranking in Rheumatology and Medicine (miscellaneous) and Q2 in Immunology, reflecting its significant contribution to these vital areas of medical research. The journal is indexed in Scopus, with a commendable rank in the 67th percentile for Rheumatology, making it a valuable resource for those seeking the latest insights into lupus management and treatment. The journal emphasizes the importance of open access, ensuring that research findings are widely available to enhance global knowledge and collaboration in the fight against lupus.

The Journal of Allergy and Clinical Immunology-In Practice, published by ELSEVIER, stands as a leading platform in the field of allergy and immunology, specifically tailored for practitioners and researchers. With an impressive 2023 Q1 ranking in both the Immunology and Allergy categories, this journal demonstrates a significant impact within the academic community, evidenced by its Scopus rank #41 out of 233 and an impressive percentile rank of 82. The journal focuses on providing advanced studies, clinical findings, and innovative treatment methodologies that address current challenges in allergy and immunology, making it a vital resource for professionals in these fields. With a comprehensive coverage of relevant topics from 2013 to 2024, the journal continues to evolve alongside emerging trends and developments in clinical practice, fostering an environment conducive to scholarly research and application. Although it currently does not offer open access, authors and readers can access a wealth of information and contribute to ongoing dialogues through its robust publication platform.

World Allergy Organization Journal is a premier open-access publication dedicated to advancing the understanding and treatment of allergic diseases and related conditions. Published by ELSEVIER, this journal boasts a commendable impact factor and ranks in the second quartile for both Immunology and Allergy, as well as the first quartile in Pulmonary and Respiratory Medicine. Since its inception as an open-access journal in 2008, it has consistently aimed to provide a credible platform for researchers, clinicians, and students to disseminate original research, reviews, and clinical studies. With its emphasis on high-quality scholarship and practical applications, the World Allergy Organization Journal plays a crucial role in bridging theoretical knowledge with clinical practice, making significant contributions to the fields of immunology, allergy, and respiratory medicine. The journal is particularly notable for its accessibility to a global audience, exemplified by its open-access model since 2008, promoting a wider exchange of ideas and innovations across borders.

Asia Pacific Allergy, published by Lippincott Williams & Wilkins, is a prominent academic journal dedicated to advancing research and clinical practice in the fields of dermatology, immunology, and allergy. With its ISSN 2233-8276 and E-ISSN 2233-8268, the journal provides a platform for innovative studies and reviews that cater to an international audience of researchers, healthcare professionals, and students involved in allergy and related disorders. Although it does not currently offer open access to its publications, the journal's robust output from 2015 to 2017 and its ongoing contribution to the literature from 2021 to 2024 showcase the evolving landscape of allergy research in the Asia Pacific region. Recognized in the 2023 Journal Citation Reports, it holds a Q2 ranking in Dermatology and a Q3 ranking in Immunology and Allergy, while its Scopus ranks further emphasize its significance within these domains, positioning it among the top journals in the field. As a source of cutting-edge research, Asia Pacific Allergy plays a vital role in fostering collaboration and knowledge dissemination, ultimately assisting in the betterment of patient care and treatment strategies across the region.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY is a premier peer-reviewed journal published by Elsevier Science Inc, dedicated to advancing the fields of allergy, asthma, and immunology. With its roots dating back to 1995 and with a focus on high-impact research, this journal has established itself as a leading platform for the dissemination of original research, reviews, and clinical studies within these critical areas. The journal boasts an impressive impact factor, supporting its Q2 ranking in both Immunology and Allergy, as well as in Pulmonary and Respiratory Medicine, indicating its significant contribution to the scientific community. Although it does not currently offer open access options, its comprehensive coverage and rigorous peer-review process ensure that published articles are of the highest quality, making it an invaluable resource for researchers, clinicians, and students alike. The Scopus rankings reflect its esteemed position in the academic landscape, providing professionals with access to cutting-edge developments and insights into the management and treatment of allergic and respiratory conditions.

Allergy Asthma and Clinical Immunology, a pioneering open access journal published by BMC, has been at the forefront of immunological research since its inception in 2005. With an ISSN of 1710-1492, this UK-based journal has established a significant presence in the fields of Immunology, Allergy, and Pulmonary and Respiratory Medicine, achieving notable quartile rankings such as Q2 in Immunology and Allergy in 2023. It plays a crucial role in disseminating high-quality research that advances our understanding of allergy and asthma, making substantial contributions to clinical practices and public health. The journal embraces the principles of Open Access, allowing researchers, professionals, and students from around the globe to access its content freely, thus facilitating knowledge sharing and collaboration within the scientific community. As it converges towards 2024, Allergy Asthma and Clinical Immunology continues to attract impactful studies that drive innovation and improve patient care in the face of rapidly evolving challenges in immunological health.